search
Back to results

A Prospective Evaluation of the Catheter Science M3 "Mini Catheter" for Patients With Prostatic

Primary Purpose

Urinary Retention

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
M3 "MINI CATHETER"
Sponsored by
Dr. Gaines W. Hammond Jr. MD FACS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urinary Retention

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Males > 50 years of age
  • Signed subject informed consent (see Appendix "A")
  • Patients with actual urinary retention dependent on Foley Catheter or Intermittent Catheter
  • Inclusion will start once the M3 is placed and a functioning bladder is demonstrated.

Exclusion Criteria:

  • Inability to undergo bladder catheterization with the M3 due to anatomical challenges (i.e. urethral stricture, bladder neck contracture, false passage or false passages or other history of urethral stricture)
  • Gross hematuria
  • Hypotonic Neurogenic Bladder (the placement of the M3 may isolate the cause of the retention with the bridging of the prostate as bladder dysfunction rather than prostate obstruction).

Sites / Locations

  • Watson Clinic LlpRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

For a single-arm trial

Arm Description

Inclusion Criteria with intervention replacing either a foley catheter or self intermittent catheter with the M3 "Mini Catheter" Males > 50 years of age Signed subject informed consent Patients with actual urinary retention dependent on Foley Catheter or Intermittent Catheter Inclusion will start once the M3 is placed and a functioning bladder is demonstrated. Exclusion Criteria Inability to undergo bladder catheterization with the M3 due to anatomical challenges (i.e. urethral stricture, bladder neck contracture, false passage or false passages or other history of urethral stricture) Gross hematuria Hypotonic Neurogenic Bladder (the placement of the M3 may isolate the cause of the retention with the bridging of the prostate as bladder dysfunction rather than prostate obstruction).

Outcomes

Primary Outcome Measures

The percentage of Catheter Acquired Urinary Tract Infections with the M3 Mini Catheter.
1.The study purpose is to measure the rate of catheter-related urinary tract infections in patients with the M3 in place as compared to the known infection rate for patients with a Foley catheter in place over the same period of time.
The percentage of M3 removed due to encrustation and blockage of the M3.
The percentage of M3 devices removed due to urinary retention caused by device encrustation.
Measurement of Bladder Drainage
The Post Void Residual after M3 placement
Flow Rate after M3 placement
The flow rate after M3 placement with a bladder volume of at least 120 cc.

Secondary Outcome Measures

Failure of the M3 as a choice of bladder drainage over Foley Catheter or Self Intermittent Catheter drainage
The failure of the M3 to drain the bladder with the requirement to reinstitute Foley Drainage or Self Intermittent Catheter by choice versus M3 Mini Catheter

Full Information

First Posted
October 24, 2017
Last Updated
November 18, 2017
Sponsor
Dr. Gaines W. Hammond Jr. MD FACS
search

1. Study Identification

Unique Protocol Identification Number
NCT03339076
Brief Title
A Prospective Evaluation of the Catheter Science M3 "Mini Catheter" for Patients With Prostatic
Official Title
A Prospective Evaluation of the Catheter Science M3 "Mini Catheter" for Patients With Prostatic
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Unknown status
Study Start Date
July 7, 2017 (Actual)
Primary Completion Date
March 2018 (Anticipated)
Study Completion Date
March 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dr. Gaines W. Hammond Jr. MD FACS

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The Catheter Science M3 "Mini Catheter" has been developed for management of urinary retention. This temporary device allows for normal functioning of the external striated sphincter. The design contributes to its atraumatic insertion and removal. It is a short catheter segment which is attached to a monofilament suture which runs thru the lumen of the urethra and is attached to a small plastic "bobber". This study is designed to validate the reduction in these adverse effects: The suture to the outside allows for repositioning should the device slip back into the bladder and facilitates removal. With volitional voiding and competent external sphincter, patients are able to void spontaneously without the need of a collection device and are continent. The design enhances the flow characteristics and reduces post void residual. Since the M3 does not have a tubular segment thru the tip of the penis or sphincter, biofilm production is eliminated.
Detailed Description
This single arm, prospective study is designed to produce valid scientific evidence regarding: Safety and efficacy of the Catheter Science M3 "Mini Catheter" in establishing urinary drainage and allowing the control of micturition when indwelling for a period of time up to but less than 28 days in male patients with prostate outlet obstruction who have been dependent on either a Foley catheter or Intermittent Catheterization. The study purpose is to measure the rate of catheter-related urinary tract infections in patients with the M3 in place as compared to the known infection rate for patients with a Foley catheter in place over the same period of time. A single arm study design was chosen because there is no alternative treatment to serve as an appropriate control. The M3 de-obstructs the prostatic urethra, allows volitional voiding function in patients with a contractile bladder. A Foley catheter, a pre- amendment device, was considered for a control treatment. Although a Foley catheter is used to establish urinary drainage initially with close to 100% efficacy, it does not allow for voluntary micturition as defined with the coordination of contraction of the bladder with the relaxation of the striated external sphincter. The ability of the bladder to fill and contract with a Foley is altered. The M3 allows for the bladder to fill since the sphincter is not bridged. Volitional micturition is initiated with bladder contraction coordinated with a relaxation of the external striated sphincter. The flow of urine is thru and around the M3 rather than only intraluminal in the Foley. The direction of urine flow with the M3 is in one direction in contrast to the Foley catheter and external collection device which is bi-directionally. The flow of urine back into the bladder has long been viewed as a significant contributor to the CAUTI. The Foley is a passive drainage device which simply drains the bladder with negative pressure produced in a closed system aided with gravity. The laterally placed intake eyes of the Foley are vulnerable to occlusion of the bladder mucosa being pulled into the lumen by the negative pressure of the closed system. The requirement of an external collecting bag coupled with the Foley traversing the entire length of the Urethra, severely impairs activities of daily life. The comparative lifestyle changes between the Foley Catheter, Intermittent Catheter and M3 group is not the focus of this study of the Safety and Efficacy characteristics of the M3 vs Foley comparison, but will be obvious to patients and clinicians. The retention balloon inflation channel impacts the internal diameter of the Foley. The Balloon prevents complete emptying of the bladder with resultant residual of 10-100cc reported. Since there is no consistent flow of urine around a Foley to help "wash out bacteria" the formation of biofilm is accelerated. The Foley violates the anatomical protective points (penile meatus, sphincter, prostatic urethral and bladder neck) which help prevent bacterial contamination. The M3 CAUTI reduction as compared to the Foley and Intermittent Catheter Group is due to a series of important design features. The removal of a retention balloon allows for the internal diameter to be enlarged. The 3 wings Malecott promotes retention of the device as well as preventing bladder mucosal plugging of the lumen during voiding contractions. This design also promotes an improved post void residual compared to a Foley device. The residual urine in the bladder with a Foley as well a slow flow rate promotes encrustations and occlusion of the Foley.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Retention

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This single arm prospective study is designed to produce valid scientific evidence regarding safety and efficacy of the M3 in establishing urinary drainage and allowing the control of micturition when indwelling for <28 days in male patients. The total study population will initially include 50 subjects with open enrollment of additional subjects. 1. Study Timeline and Calendar The maximum indwelling time for the DEVICE should be <28 days, at which time the DEVICE will be removed, and the patient will be offered the option of insertion of a new M3 Catheter or return to the bladder drainage technique used prior to M3 Catheter insertion. All patients will be followed until patient is off study or until end of study, whichever occurs first.
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
For a single-arm trial
Arm Type
Other
Arm Description
Inclusion Criteria with intervention replacing either a foley catheter or self intermittent catheter with the M3 "Mini Catheter" Males > 50 years of age Signed subject informed consent Patients with actual urinary retention dependent on Foley Catheter or Intermittent Catheter Inclusion will start once the M3 is placed and a functioning bladder is demonstrated. Exclusion Criteria Inability to undergo bladder catheterization with the M3 due to anatomical challenges (i.e. urethral stricture, bladder neck contracture, false passage or false passages or other history of urethral stricture) Gross hematuria Hypotonic Neurogenic Bladder (the placement of the M3 may isolate the cause of the retention with the bridging of the prostate as bladder dysfunction rather than prostate obstruction).
Intervention Type
Device
Intervention Name(s)
M3 "MINI CATHETER"
Intervention Description
Participants in the study are using either a foley catheter or Clean Intermittent Catheter devices to facilitate bladder drainage. The study is an alternative method of facilitating bladder drainage with the M3 "Mini Catheter."
Primary Outcome Measure Information:
Title
The percentage of Catheter Acquired Urinary Tract Infections with the M3 Mini Catheter.
Description
1.The study purpose is to measure the rate of catheter-related urinary tract infections in patients with the M3 in place as compared to the known infection rate for patients with a Foley catheter in place over the same period of time.
Time Frame
Time of placement up to 28 days.
Title
The percentage of M3 removed due to encrustation and blockage of the M3.
Description
The percentage of M3 devices removed due to urinary retention caused by device encrustation.
Time Frame
Weekly from time of placement up to 28 days.
Title
Measurement of Bladder Drainage
Description
The Post Void Residual after M3 placement
Time Frame
Weekly from time of placement up to 28 days.
Title
Flow Rate after M3 placement
Description
The flow rate after M3 placement with a bladder volume of at least 120 cc.
Time Frame
At time of placement and weekly up to 28 days.
Secondary Outcome Measure Information:
Title
Failure of the M3 as a choice of bladder drainage over Foley Catheter or Self Intermittent Catheter drainage
Description
The failure of the M3 to drain the bladder with the requirement to reinstitute Foley Drainage or Self Intermittent Catheter by choice versus M3 Mini Catheter
Time Frame
From time of Placement up to 28 days.

10. Eligibility

Sex
Male
Gender Based
Yes
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Males > 50 years of age Signed subject informed consent (see Appendix "A") Patients with actual urinary retention dependent on Foley Catheter or Intermittent Catheter Inclusion will start once the M3 is placed and a functioning bladder is demonstrated. Exclusion Criteria: Inability to undergo bladder catheterization with the M3 due to anatomical challenges (i.e. urethral stricture, bladder neck contracture, false passage or false passages or other history of urethral stricture) Gross hematuria Hypotonic Neurogenic Bladder (the placement of the M3 may isolate the cause of the retention with the bridging of the prostate as bladder dysfunction rather than prostate obstruction).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
GAINES W HAMMOND, MD
Phone
863-687-1322
Email
GHAMMOND@WATSONCLINIC.COM
First Name & Middle Initial & Last Name or Official Title & Degree
ELAYNE HALL
Phone
863-680-7300
Email
EHALL@WATSONCLINIC.COM
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GAINES W HAMMOND, MD
Organizational Affiliation
Watson Clinic Center for Research, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Watson Clinic Llp
City
Lakeland
State/Province
Florida
ZIP/Postal Code
33805
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
GAINES W HAMMOND, MD
Phone
863-680-7300
Email
GHAMMOND@WATSONCLINIC.COM
First Name & Middle Initial & Last Name & Degree
ELAYNE HALL
Phone
863-680-7300
Email
EHALL@WATSONCLINIC.COM

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
There is a plan to make IPD and related data dictionaries available.
IPD Sharing Time Frame
After completion of the study anticipated to be in March 2018 for a 2 year period of time.
IPD Sharing Access Criteria
Appropriate credentials to access material with the identifying markers of patients identity withheld.

Learn more about this trial

A Prospective Evaluation of the Catheter Science M3 "Mini Catheter" for Patients With Prostatic

We'll reach out to this number within 24 hrs